Remove tag ketamine
article thumbnail

J&J builds case for antidepressant Spravato with head-to-head trial

pharmaphorum

One issue has been the cost of the drug, with health technology assessment agency NICE in the UK and the ICER organisation in the US both concluding its price tag means it is not a cost-effective option for health systems. The post J&J builds case for antidepressant Spravato with head-to-head trial appeared first on.

article thumbnail

Walking Each Other Home with Community-Based Psychedelic Support

The Spirit Pharmacist

However, psychedelic assisted therapy is resource intensive and will likely come with a price tag putting it out of reach of many persons that could benefit from such therapies. I'm also giving a talk for them this coming Thursday, December 9th at 6pm PST.